Portal de investigação
Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey
Autores da FMUP
Participantes de fora da FMUP
- Saliba, G
- Detlefsen, S
- Conner, J
- Dorer, R
- Fléjou, JF
- Hahn, H
- Kamaradova, K
- Mastracci, L
- Meijer, SL
- Sabo, E
- Sheahan, K
- Riddell, R
- Wang, N
- Yantiss, RK
- Lundell, L
- Low, D
- Vieth, M
- Klevebro, F
Unidades de investigação
Abstract
Complete histopathologic tumor regression after neoadjuvant treatment is a well-known prognostic factor for survival among patients with adenocarcinomas of the esophagus and gastroesophageal junction. The aim of this international Delphi survey was to reach a consensus regarding the most useful tumor regression grading (TRG) system that could represent an international standard for histopathologic TRG grading of gastroesophageal carcinomas. Fifteen pathologists with special interest in esophageal and gastric pathology participated in the online survey. The initial questionnaire contained of 43 statements that addressed the following topics: (1) specimen processing, (2) gross examination, (3) cross sectioning, (4) staining, (5) Barrett's esophagus, (6) TRG systems, and (7) TRG in lymph node (LN). Participants rated the items using a 5-point Likert style scale and were encouraged to write comments for each statement. The expert panel recommended a 4-tiered TRG system for assessing the primary tumor: grade 1: No residual tumor (complete histopathologic tumor regression), grade 2: less than 10% residual tumor (near-complete regression), grade 3: 10%-50% residual tumor (partial regression), grade 4: greater than 50% residual tumor (minimal/no regression), combined with a 3-tiered system for grading therapeutic response in metastatic LNs: grade a: no residual tumor (complete histopathologic TRG), grade b: partial regression (tumor cells and regression), grade c: no regression (no sign of tumor response). This TRG grading system can be recommended as an international standard for histopathologic TRG grading in esophageal and gastroesophageal junction adenocarcinoma. (C) 2020 Elsevier Inc. All rights reserved.
Dados da publicação
- ISSN/ISSNe:
- 1532-8392, 0046-8177
- Tipo:
- Article
- Páginas:
- 60-67
- Link para outro recurso:
- www.scopus.com
Human Pathology W.B. Saunders Ltd
Citações Recebidas na Web of Science: 11
Citações Recebidas na Scopus: 13
Documentos
- Não há documentos
Filiações
Keywords
- Esophageal cancer; Gastroesophageal junction cancer; Neoadjuvant treatment; Histopathologic tumor regression grade; Delphi; Consensus
Campos de estudo
Proyectos asociados
Gastric Cancer Morphological, Immunophenotypic and molecular heterogeneity
Investigador Principal: Maria de Fátima Machado Henriques Carneiro
Estudo Clínico Académico . 2020
Citar a publicação
Saliba G,Detlefsen S,Carneiro F,Conner J,Dorer R,Fléjou JF,Hahn H,Kamaradova K,Mastracci L,Meijer SL,Sabo E,Sheahan K,Riddell R,Wang N,Yantiss RK,Lundell L,Low D,Vieth M,Klevebro F. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey. Hum. Pathol. 2021. 108. p. 60-67. IF:3,526. (2).
